Michele Simonetti

Michele Simonetti

Auto-generated profile, based on publicly available information

Michele Simonetti

Pixelgen Technologies AB, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2024 in Nature Methods
Verified
Journal Article
Open access
PDF file
FKFilip Karlsson
Filip Karlsson
TKTomasz Kallas
Tomasz Kallas
DTDivya Thiagarajan
Divya Thiagarajan
MKMax Karlsson
Max Karlsson
MSMaud Schweitzer
Maud Schweitzer
SFSimon Fredriksson
Simon Fredriksson
The spatial distribution of cell surface proteins governs vital processes of the immune system such as intercellular communication and mobility. However, fluorescence microscopy has limited scalability in the multiplexing and throughput needed to drive spatial proteomics discoveries at subcellular level. We present Molecular Pixelation (MPX), an optics-free, DNA sequence-based method for spatial proteomics of single cells using antibody–oligonucleotide conjugates (AOCs) and DNA-based, nanometer-sized molecular pixels. The relative locations of AOCs are inferred by sequentially associating them into local neighborhoods using the sequence-unique DNA pixels, forming >1,000 spatially connected zones per cell in 3D. For each single cell, DNA-sequencing reads are computationally arranged into spatial proteomics networks for 76 proteins. By studying immune cell dynamics using spatial statistics on graph representations of the data, we identify known and new patterns of spatial organization of proteins on chemokine-stimulated T cells, highlighting the potential of MPX in defining cell states by the spatial arrangement of proteins.

23 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMichele Simonetti
Michele Simonetti
NZNing Zhang
Ning Zhang
LHLuuk Harbers
Luuk Harbers
MMMaria Grazia Milia
Maria Grazia Milia
SBSilvia Brossa
Silvia Brossa
NCNicola Crosetto
Nicola Crosetto
While mass-scale vaccination campaigns are ongoing worldwide, genomic surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to monitor the emergence and global spread of viral variants of concern (VOC). Here, we present a streamlined workflow—COVseq—which can be used to generate highly multiplexed sequencing libraries compatible with Illumina platforms from hundreds of SARS-CoV-2 samples in parallel, in a rapid and cost-effective manner. We benchmark COVseq against a standard library preparation method (NEBNext) on 29 SARS-CoV-2 positive samples, reaching 95.4% of concordance between single-nucleotide variants detected by both methods. Application of COVseq to 245 additional SARS-CoV-2 positive samples demonstrates the ability of the method to reliably detect emergent VOC as well as its compatibility with downstream phylogenetic analyses. A cost analysis shows that COVseq could be used to sequence thousands of samples at less than 15 USD per sample, including library preparation and sequencing costs. We conclude that COVseq is a versatile and scalable method that is immediately applicable for SARS-CoV-2 genomic surveillance and easily adaptable to other pathogens such as influenza viruses.

24 April 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
NZNing Zhang
Ning Zhang
LHLuuk Harbers
Luuk Harbers
MSMichele Simonetti
Michele Simonetti
CDConstantin Diekmann
Constantin Diekmann
QVQuentin Verron
Quentin Verron
NCNicola Crosetto
Nicola Crosetto
Somatic copy number alterations (SCNAs) are pervasive in advanced human cancers, but their prevalence and spatial distribution in early-stage, localized tumors and their surrounding normal tissues are poorly characterized. Here, we perform multi-region, single-cell DNA sequencing to characterize the SCNA landscape across tumor-rich and normal tissue in two male patients with localized prostate cancer. We identify two distinct karyotypes: ‘pseudo-diploid’ cells harboring few SCNAs and highly aneuploid cells. Pseudo-diploid cells form numerous small-sized subclones ranging from highly spatially localized to broadly spread subclones. In contrast, aneuploid cells do not form subclones and are detected throughout the prostate, including normal tissue regions. Highly localized pseudo-diploid subclones are confined within tumor-rich regions and carry deletions in multiple tumor-suppressor genes. Our study reveals that SCNAs are widespread in normal and tumor regions across the prostate in localized prostate cancer patients and suggests that a subset of pseudo-diploid cells drive tumorigenesis in the aging prostate.

19 November 2021 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
IZIoannis Zerdes
Ioannis Zerdes
MSMichele Simonetti
Michele Simonetti
AMAlexios Matikas
Alexios Matikas
LHLuuk Harbers
Luuk Harbers
BABalazs Acs
Balazs Acs
TFTheodoros Foukakis
Theodoros Foukakis
Emerging data indicate that genomic alterations can shape immune cell composition in early breast cancer. However, there is a need for complementary imaging and sequencing methods for the quantitative assessment of combined somatic copy number alteration (SCNA) and immune profiling in pathological samples. Here, we tested the feasibility of three approaches—CUTseq, for high-throughput low-input SCNA profiling, multiplexed fluorescent immunohistochemistry (mfIHC) and digital-image analysis (DIA) for quantitative immuno-profiling- in archival formalin-fixed paraffin-embedded (FFPE) tissue samples from patients enrolled in the randomized SBG-2004-1 phase II trial. CUTseq was able to reproducibly identify amplification and deletion events with a resolution of 100 kb using only 6 ng of DNA extracted from FFPE tissue and pooling together 77 samples into the same sequencing library. In the same samples, mfIHC revealed that CD4 + T-cells and CD68 + macrophages were the most abundant immune cells and they mostly expressed PD-L1 and PD-1. Combined analysis showed that the SCNA burden was inversely associated with lymphocytic infiltration. Our results set the basis for further applications of CUTseq, mfIHC and DIA to larger cohorts of early breast cancer patients.

24 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
FKFilip Karlsson
Filip Karlsson
MSMichele Simonetti
Michele Simonetti
CGChristina Galonska
Christina Galonska
MKMax Jonatan Karlsson
Max Jonatan Karlsson
HOHanna van Ooijen
Hanna van Ooijen
SFSimon Fredriksson
Simon Fredriksson
Cellular function depends on dynamic interactions and nanoscale spatial organisation of proteins. While transcriptomic and proteomic methods have enabled single-cell profiling, scalable technologies allowing high-resolution analysis of protein interactions at omics-scale are lacking. Here we present the Proximity Network Assay (PNA), a DNA-based method for constructing three-dimensional nanoscale maps of 155 proteins in single cells without the use of optics. PNA employs barcoded antibodies and in situ rolling circle amplification to generate >40,000 spatial nodes per cell, which are linked through proximity-dependent gap-fill ligation and decoded by DNA sequencing, forming single cell Proximity Networks. At an estimated spatial resolution of ∼50 nm, PNA captures single-cell protein abundance, self-clustering, and colocalization, validating established cell membrane protein interactions. We illustrate how PNA can be used to gain insights into the molecular mechanisms of cell function through protein interactions in hematological oncology, CAR-T cell therapies, and autoimmune disease.

11 February 2022 in Research Square
Verified
Preprint
Open access
PDF file
MNMarcin Nicos
Marcin Nicos
LHLuuk Harbers
Luuk Harbers
EPEnrico Patrucco
Enrico Patrucco
MKMaximilian Kramer-Drauberg
Maximilian Kramer-Drauberg
XZXiaolu Zhang
Xiaolu Zhang
NCNicola Crosetto
Nicola Crosetto
Brain metastases (BM) severely impact the prognosis and quality of life of patients with non-small cell lung cancer (NSCLC). To identify targetable drivers of NSCLC-BM, we profiled somatic copy number alterations (SCNAs) in 51 matched pairs of primary NSCLC and BM samples from 33 patients with lung adenocarcinoma (LUAD) and 18 patients with lung squamous cell carcinoma (LUSC). BM consistently had a higher burden of SCNAs compared to the matched primary tumors, and SCNAs were typically homogeneously distributed within BM, as revealed by multi-region SCNA profiling in 15 BM samples, suggesting that BM do not undergo extensive evolution once formed. By comparing focal SCNAs in matched NSCLC-BM pairs, we identified BM driving alterations affecting multiple cancer genes, including several targetable genes such as CDK12, DDR2, ERBB2, and NTRK1, which we validated in an independent cohort of 84 BM samples. We explored the metastatic potential of CDK12 and DDR2 in vitro and in vivo and found that overexpression of either gene alone in murine lung cancer cells causes the induction of key genes involved in epithelial-mesenchymal transition. Finally, we performed whole-exome sequencing of 40 NSCLC-BM pairs and identified BM driver mutations in multiple cancer genes, including several genes involved in epigenome editing and 3D genome organization, such as EP300, CTCF, and STAG2, which we validated by targeted sequencing of an independent cohort of 115 BM samples. Our study represents the most comprehensive genomic characterization of LUAD and LUSC BM available to date, uncovering potentially targetable NSCLC-BM drivers and inspiring the design of novel precision treatment strategies for NSCLC patients.